The sites of amino acid residues most frequently involved in resistance to protease inhibitors are shown as red beads. The designation of the corresponding residues is written in red for the first ...

One compound in particular, GRL-0519A, shows remarkable protease inhibition and antiviral activity. Moreover, this compound is extremely potent against various multidrug-resistant HIV-1 variants ...

Mutations in gag can act as compensatory substitutions that can increase both rates and levels of resistance to protease inhibitors, as well as viral replication capacity. 78 No genotypic system ...

Pre-existing resistance may reduce the efficacy of the protease inhibitor darunavir, a study published in the September 12 th edition of AIDS suggests. French investigators found that both baseline ...

Additionally, mutations in the viral envelope protein, which is involved in cell entry, were associated with resistance to protease inhibitor treatment. In the accompanying Attending Physician ...

The prevalence of HIV resistance to protease inhibitors fell sharply between 2003 and 2010, according to a study presented to the 51 st ICAAC meeting in Chicago. Investigators from Monogram ...

while the triple mutant L50F+E166A+L167F resulted in the highest levels of resistance (72-fold). All substitutions were associated with a significant loss of protease activity, suggesting a ...

The clinical protease inhibitors resistant to Paxlovid’s active drug, nirmatrelvir, are ∆P168, A173V, A173T, T45I and D48Y. The ∆P168 variant showed a 5.1 times increased resistance ...

Additionally, mutations in the viral envelope protein, which is involved in cell entry, were associated with resistance to protease inhibitor treatment. In the accompanying Attending Physician ...